Dr. Graham Belfield

AstraZeneca

The medicine revolution: Turning disease biology into predictive science

In this video, Dr. Graham Belfield shares how the Discovery Science group at AstraZeneca is working to gather observational information from patient-derived material to better understand human disease and treatment and create predictive models that can reduce attrition in the clinic and ultimately develop more effective medicines that reach more patients.



LIKE 2


Dr. Graham Belfield
Disease Models Genetic Analysis SLAS

Dr. Graham Belfield

Biography

Director NGS & Transcriptomics, AstraZeneca More
Follow Graham

Dr. Graham Belfield

AstraZeneca

Dr. Graham Belfield has over 35 years’ experience across pharma, biotech, and academia, applying transcriptomics, bioinformatics, orthogonal functional genetics, and biotechnology to the discovery of new medicines. He leads a research-orientated Nucleic Acids Omics laboratory that partners pre-clinical/clinical projects across the whole of AstraZeneca and with academic collaborators. Focusing on NGS and associated technologies, his work generates transcriptomic, epigenetic, and genetic smart data for both single and multi-omic projects. To this end, he employs bulk, single-cell, spatial, short- and long-read technologies together with automation. Belfield’s work aims to stretch these technologies to increase the value they bring to drug discovery and enhancing understanding of disease and the fundamental processes of biology.